Hydroxychloroquine, sold under the brand name Plaquenil and widely referred to by patients simply as HCQ, is one of the most commonly prescribed medications for Sjögren's syndrome. It is not, however, a proven cure, and the best-designed clinical trial to date did not find that it clearly relieves the dryness and fatigue that define this disease. This article lays out plainly what the research actually shows, how the drug is typically dosed, how long it takes to judge whether it is working, and what monitoring a patient should expect while taking it.

What Sjögren's Syndrome Actually Is

Sjögren's syndrome is a chronic autoimmune disease in which the immune system mistakenly infiltrates and damages the body's moisture-producing glands, principally the salivary and lacrimal glands. The hallmark symptoms are persistent dry mouth (xerostomia) and dry, gritty, burning eyes (keratoconjunctivitis sicca), but the disease is rarely confined to the eyes and mouth. Many patients also experience joint pain, profound fatigue, dry skin, vaginal dryness, and, less commonly, inflammation of the lungs, kidneys, nerves, or blood vessels. When it occurs on its own it is called primary Sjögren's syndrome; when it accompanies another autoimmune condition such as rheumatoid arthritis or lupus, it is termed secondary Sjögren's.

The exact cause is not fully understood, but it involves a genetic predisposition interacting with environmental triggers, most plausibly certain viral infections, in a body whose immune surveillance turns against its own gland tissue. Roughly nine out of ten patients are women, and the disease most often appears in midlife, which points toward a hormonal contribution as well. Most patients carry distinctive autoantibodies, anti-Ro/SSA and anti-La/SSB, which are useful for diagnosis and help identify which patients are more likely to have systemic, rather than purely glandular, involvement. Sjögren's also carries a modestly increased lifetime risk of lymphoma, which is one reason rheumatologists monitor patients over time rather than treating dryness in isolation.

Why Hydroxychloroquine Is Used Here at All

Hydroxychloroquine descends from quinine, the anti-malarial compound first isolated from the bark of the South American cinchona tree, a reminder that some of medicine's most durable tools were sitting quietly in creation long before anyone understood how to use them. In autoimmune disease, hydroxychloroquine works differently than it does against malaria parasites. It accumulates inside immune cells and interferes with antigen processing and toll-like receptor signaling, which dampens the overactive immune response without broadly suppressing the whole immune system the way stronger drugs do. This is why it has an established role in lupus and rheumatoid arthritis, and why rheumatologists reasoned it should help Sjögren's as well.

It is important for patients to know that hydroxychloroquine is not FDA-approved specifically for Sjögren's syndrome. Its approved uses are malaria, lupus, and rheumatoid arthritis. Its use in Sjögren's is what physicians call "off-label," meaning a doctor is applying an approved drug to a related condition based on clinical judgment and the available evidence, which is entirely legal and common practice in rheumatology, but it is worth understanding that the regulatory approval and the everyday prescribing pattern are not the same thing.

What the Evidence Actually Shows

The strongest test of hydroxychloroquine in Sjögren's syndrome is the JOQUER trial, a multicenter, randomized, double-blind, placebo-controlled study run by French rheumatology investigators and published in the journal Arthritis & Rheumatology around 2014. Roughly 120 patients with primary Sjögren's syndrome were randomized to hydroxychloroquine or placebo and followed for six months. The trial's primary endpoint combined patient-reported dryness, pain, and fatigue on visual analog scales. The result was a negative one: there was no statistically significant difference between hydroxychloroquine and placebo on that composite measure. This is a genuinely important finding, and it is the reason a careful clinician will not promise a patient that hydroxychloroquine will resolve dry eyes or dry mouth.

That said, the trial and subsequent analyses were not entirely without signal. Some secondary and biological measures, including markers of B-cell activation, immunoglobulin levels, and inflammatory markers such as ESR, tended to improve with treatment even when the core symptom scores did not move significantly. Larger observational cohort studies, including analyses drawn from international Sjögren's registries, have reported that patients treated with hydroxychloroquine tend to show lower rates of hypergammaglobulinemia and lower systemic disease activity scores over time compared with untreated patients, and some registry analyses have suggested an association with a lower incidence of lymphoma. These findings are hypothesis-generating rather than proof; observational data of this kind cannot rule out that healthier or less severely affected patients were simply more likely to be prescribed the drug in the first place, a form of selection bias that randomized trials are designed to avoid.

For comparison, other systemic treatments tested for Sjögren's have also struggled to clear the bar of rigorous trials. The TRACTISS trial in the United Kingdom tested rituximab, a much stronger biologic, against placebo and likewise failed to meet its primary endpoint for dryness and fatigue. This pattern across multiple drug classes suggests the difficulty lies partly in the disease itself, which mixes glandular damage that may not be reversible with inflammation that might respond to treatment, making symptom scores a blunt instrument for measuring benefit.

Taken together, the honest summary is this: hydroxychloroquine has a plausible mechanism, a long safety track record in related autoimmune diseases, and observational support for modest effects on systemic inflammation, but it has not been shown in a well-controlled trial to reliably relieve the sicca symptoms that most patients care about most. Many rheumatologists still prescribe it, reasonably, for its effects on joint pain, fatigue, and inflammatory markers, and because the alternative systemic options carry more risk for uncertain additional benefit.

Dosing and What to Expect Over Time

When hydroxychloroquine is prescribed for Sjögren's syndrome, dosing follows the same weight-based principle used in lupus and rheumatoid arthritis. Current ophthalmology and rheumology guidance recommends a maximum of about 5 milligrams per kilogram of actual body weight per day, a threshold established after research clarified that older, higher dosing regimens carried meaningfully more risk of eye toxicity. In practice, this usually translates to 200 mg once or twice daily for an average-sized adult, sometimes adjusted downward for smaller patients.

Patients should not expect a fast result. As with lupus and rheumatoid arthritis, hydroxychloroquine works gradually, by slowly recalibrating immune activity rather than blocking a single inflammatory pathway outright. Most rheumatologists advise giving it a minimum of eight to twelve weeks before judging whether it is helping, and a fuller assessment of benefit, particularly for joint pain and fatigue, often takes three to six months. Because the JOQUER trial found no clear effect on core dryness at six months, patients should be realistic that hydroxychloroquine is not primarily a dry-eye or dry-mouth treatment; those symptoms are generally managed directly with artificial tears, punctal plugs, saliva substitutes, and, when appropriate, muscarinic agonist medications such as pilocarpine or cevimeline that stimulate the remaining functional gland tissue.

Safety and the Monitoring That Should Come With It

Hydroxychloroquine has an unusually long safety record compared with many rheumatologic drugs, having been used for malaria prevention and lupus for decades. Common early side effects include nausea, mild gastrointestinal upset, and headache, which often improve after the first few weeks. Skin rash and, rarely, changes in blood counts can occur and warrant a call to your physician.

The one monitoring requirement that should never be skipped is regular eye examination. Hydroxychloroquine can, in a small proportion of long-term users, cause a specific retinal toxicity that is largely painless in its early stages but can progress and is not reversible once advanced. The American Academy of Ophthalmology's revised 2016 guidance recommends a baseline eye exam when starting the drug and annual screening beginning after five years of use for patients at average risk, using optical coherence tomography and visual field testing, with earlier and more frequent monitoring for those with kidney impairment, very high cumulative dose, concurrent tamoxifen use, or pre-existing retinal disease. This is a case where personal responsibility matters enormously: keeping scheduled eye appointments, even when vision feels fine, is the single most effective safeguard against this rare but serious complication, and it is squarely within a patient's own power to keep that appointment on the calendar.

Putting It All Together

There is no single "best" treatment for Sjögren's syndrome because the disease itself is not singular; it ranges from isolated dryness to serious systemic organ involvement, and care has to be matched to the individual patient rather than applied as a formula. For most patients, management begins with direct, local relief of dryness, moves on to hydroxychloroquine when joint pain, fatigue, or systemic inflammatory markers justify it, and reserves stronger immunosuppressive or biologic agents for the minority with significant organ-threatening disease. A patient who understands this landscape, asks direct questions about what a medication can and cannot be expected to do, and works with a physician she trusts to weigh the trade-offs, is in a far stronger position than one who is simply told to take a pill and wait.

Key takeaway: Hydroxychloroquine is a reasonable, well-tolerated option for the joint pain, fatigue, and inflammatory activity of Sjögren's syndrome, but the best available trial evidence does not support it as a reliable treatment for the dryness itself, so expectations and eye-safety monitoring should be set accordingly with your own physician.